title: [Modified CLIP score as a new prognostic index for patients with hepatocellular carcinoma].
abstract: OBJECTIVE
  The prognosis of cirrhotic patients with hepatocellular carcinoma (HCC) depends on both residual liver function and tumor characteristics. The aims of this study was to construct a new prognostic index for HCC patients: the modified CLIP score, and to compare its discriminatory ability and predictive power with those of the CLIP score that is currently the most commonly used integrated staging score in patients of HCC.
  
  
  METHODS
  A retrospective analysis of 237 cases of HCC diagnosed at Dong-A university hospital was performed. Prognostic analysis was performed for single variables by estimating survival distributions with the Kaplan-Meier's method, and statistically compared by the log-rank test.
  
  
  RESULTS
  Patients had a mean age of 57.5 years and were predominantly males (79.7%). The overall median survival period was 25.7 months. It was correlated to ascites, portal vein thrombosis, AFP, tumor size, and Child-Pugh classification. The median survival period was 41.0, 25.2, 13.8, 13.4, and 6.5 months for CLIP scores 0, 1, 2, 3, and 4 to 6, respectively (P<0.001), and 42.1, 34.0, 25.7, 14.0, and 6.8 months for modified CLIP scores 0, 1, 2, 3, and 4 to 6, respectively (P<0.001). The Kaplan-Meier's curve showed that the modified CLIP score had additional explanatory power above that of the CLIP score.
  
  
  CONCLUSIONS
  The modified CLIP score, compared with the CLIP score, particularly in the score 2- to 3- patient groups of HCC, had greater discriminant ability and survival predictive power, but was not able to discriminate 4- to 6- patient group.
authors.affiliation: Department of Internal Medicine, Medical Sciences Research Institute of Gastroenterology, Dong-A University College of Medicine, Busan, Korea.
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Han
authors.forename: Sang Young
authors.initials: SY
authors.lastname: Han
authors.forename: Byoung Soung
authors.initials: BS
authors.lastname: Go
authors.forename: Min Ji
authors.initials: MJ
authors.lastname: Kim
authors.forename: Jung Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Young Hun
authors.initials: YH
authors.lastname: Koo
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Ryu
authors.forename: Jeong Hwan
authors.initials: JH
authors.lastname: Cho
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Jang
authors.forename: Jong Hoon
authors.initials: JH
authors.lastname: Lee
authors.forename: Myung Hwan
authors.initials: MH
authors.lastname: Roh
authors.forename: Seok Ryeol
authors.initials: SR
authors.lastname: Choi
authors.forename: Joung Chel
authors.initials: JC
authors.lastname: Choi
authors.forename: Sung Wook
authors.initials: SW
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000150:complications / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016019:Survival Analysis; D020246:Venous Thrombosis / Q000150:complications; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins